Sharemaestro Newsreel

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

Eli Lilly Commits to Veeva CRM to Bring More Medicines to Patients

Veeva Systems announced that Eli Lilly and Company will deploy Veeva Vault CRM globally. This commitment expands their strategic relationship, utilizing Veeva's AI-enabled "agentic commercial" model to help bring new medicines to more patients. The announcement highlights the continued adoption of Veeva's cloud solutions …

Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB decreased its stake in Gilead Sciences by 7.2% in the second quarter, now holding 975,089 shares valued at approximately $123.2 million. Other institutional investors have adjusted their positions, with collective institutional ownership standing at 83.67%. Gilead Sciences reported strong quarterly revenues …

Handelsbanken Fonder AB Has $125.51 Million Stake in Amgen Inc. $AMGN

Handelsbanken Fonder AB increased its stake in Amgen Inc. by 15.7% in the second quarter, now owning 346,596 shares valued at $125.51 million. Several other institutional investors also adjusted their positions in Amgen. The article also provides financial details, recent earnings, dividend information, and …

AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee …

Eli Lilly and Company $LLY Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% in the second quarter, selling 27,617 shares. Despite this sale, Eli Lilly remains a significant holding for Handelsbanken Fonder AB, representing 2.3% of its portfolio. Other institutional investors, however, increased …

Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk is expanding its collaboration with AWS to integrate agentic AI into its drug discovery processes, including target identification and therapy design. AWS will serve as Novo Nordisk's preferred cloud provider and strategic AI partner, with a co-innovation hub established in London to …

Amgen Inc. $AMGN Shares Acquired by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC increased its stake in Amgen Inc. by 38.9% in the second quarter, bringing its total holdings to 9,856 shares valued at $3.57 million. Institutional investors now own 76.5% of Amgen's stock. The company recently beat earnings expectations, reporting $6.29 EPS …

KMG Fiduciary Partners LLC Acquires 39,875 Shares of Pfizer Inc. $PFE

KMG Fiduciary Partners LLC increased its stake in Pfizer Inc. by 26.4% in the second quarter, purchasing 39,875 shares to bring its total holdings to 190,888 shares valued at approximately $4.6 million. Despite this increased institutional interest, analyst sentiment remains cautious with an average …

KMG Fiduciary Partners LLC Sells 26,888 Shares of Merck & Co., Inc. $MRK

KMG Fiduciary Partners LLC significantly reduced its stake in Merck & Co., Inc. (NYSE:MRK) by selling 26,888 shares, a 50.5% decrease, now holding 26,379 shares valued at $3.39 million. Despite this, institutional investors collectively own 76.07% of Merck's stock, and analysts maintain a "Moderate …

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.3% during the second quarter, now holding 44,792 shares valued at $5.66 million. Despite this, other institutional investors have slightly increased their holdings. Analysts currently rate GILD …

Carolina Wealth Advisors LLC Sells 15,954 Shares of Merck & Co., Inc. $MRK

Carolina Wealth Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 33.2% in the second quarter, selling 15,954 shares and now owning 32,171 shares valued at $4.13 million. The article also details other institutional investor activity, Merck's financial performance including its …

Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV

Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. by 68.6% in the second quarter, purchasing an additional 7,626 shares and bringing its total holdings to 18,741 shares valued at $4.716 million. Other institutional investors have also adjusted their positions in AbbVie, with …

First Trust Advisors LP Lowers Stock Holdings in Novo Nordisk A/S $NVO

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

Bay Colony Advisory Group Inc d b a Bay Colony Advisors Trims Stake in Merck & Co., Inc. $MRK

Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its stake in Merck & Co., Inc. by 33.4% in the second quarter, selling 10,387 shares and holding 20,685 shares valued at $2,658,000. Despite this reduction, other institutional investors increased their holdings, …

Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals

During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and …

Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions

Amgen reported strong second-quarter results, exceeding analyst estimates with double-digit growth in key products and raising full-year guidance for both revenue and adjusted EPS. The article highlights management's commentary on the breadth of their portfolio and ability to grow despite patent expirations, alongside key …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

Pfizer's Q2 earnings call highlighted the company's stable core business and strong non-COVID portfolio performance, exceeding analyst revenue and EPS estimates. Management attributed success to strategic acquisitions and effective commercial teams. Analysts' questions focused on clinical trial benchmarks, non-COVID revenue drivers, commercial potential of …

Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed

Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights – first half …

Historical marker dedicated in downtown Indy commemorating Eli Lilly and Company's founding

A historical marker has been dedicated in downtown Indianapolis to commemorate the founding of Eli Lilly and Company. The marker signifies the pharmaceutical giant's origins in the city.

VELA LARGE CAP PLUS FUND's AstraZeneca PLC(AZN) Holding History

This article details VELA LARGE CAP PLUS FUND's holding history for AstraZeneca PLC (AZN). As of March 31, 2026, the fund held 4,854 shares of AZN, valued at $957,310, constituting 1.64% of its portfolio. The initial purchase occurred in Q1 2026 at an average …

News | Bristol Myers Squibb plans $2.3 billion Houston campus

Bristol Myers Squibb announced plans for a $2.3 billion, 600,000-square-foot campus in Houston's Generation Park, expected to create nearly 500 skilled jobs by 2030. This investment is part of a larger $40 billion commitment to U.S. operations, aiming to boost domestic manufacturing and reduce …

Bristol Myers Squibb lays out plan for $2.3B manufacturing facility in Houston

Bristol Myers Squibb has announced a $2.3 billion investment to build a manufacturing campus in Houston, significantly increasing its initial estimate of $1 billion. The facility, expected to employ nearly 500 people and be completed by 2030, will produce small molecules, biologics, and antibody-drug …

OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...

This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million …

BMS Chooses Houston for $2.3B Manufacturing Facility

Bristol Myers Squibb (BMS) has selected Houston as the location for a new $2.3 billion multi-modal manufacturing campus. This facility, part of BMS's $40 billion U.S. investment, will support the production of various treatments including small molecules, biologics, and ADCs. The campus aims to …

Pharma giant bets $2.3B on massive new Houston campus

Bristol Myers Squibb has chosen Houston for a new $2.3 billion manufacturing campus at Generation Park. This massive 600,000-square-foot facility is expected to create nearly 500 skilled jobs and approximately 2,000 indirect jobs during its construction phase. The investment is part of the company's …

Sanofi Stock 12‑Month Price Target Cut to $50, Implies 15% Upside

Analysts have cut Sanofi's average 12-month price target from $50.6 to $50, with individual forecasts ranging from $45 to $57 per share. Based on the Aug. 7 closing price, this new target suggests a potential upside of approximately 15%. The consensus rating from seven …

Amgen (AMGN) director Charles Holley receives stock award and reports trust holdings

Amgen director Charles M. Holley reported receiving a compensation-related grant of 103.4189 shares of common stock on August 7, 2026. Following this award, he directly holds 12,990.4520 shares, which include Dividend Equivalents, and indirectly holds 1,260.0000 shares through the Holley Family Trust. This transaction …

Amgen (AMGN) director Michael V. Drake granted 63.8764 shares in equity award

Amgen director Michael V. Drake was granted 63.8764 shares of common stock as compensation on August 7, 2026. This automatic award, valued at $0.00 per share, increases his direct holdings to 5,876.1633 shares, which includes 377 Dividend Equivalents linked to unvested Restricted Stock Units. …

What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders

In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …

Pharma giants, including AbbVie, sue to block Illinois drug discount law

Major pharmaceutical companies, including AbbVie, Bristol Myers, and Novartis, have filed a lawsuit to block a new drug discount law in Illinois. The lawsuit challenges the state's 340B law, which aims to provide discounted prescription drugs. This legal action by the pharma giants indicates …

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate …

New Bristol Myers Squibb facility coming to Generation Park

Global biopharmaceutical company Bristol Myers Squibb is set to establish a new pharmaceutical manufacturing campus in the Houston area, specifically near Generation Park. FOX 26's Karys Belger reported on this development. The facility will mark a significant expansion for the company in the region.

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …